肿瘤细胞治疗研究
英文原题：Multi-parametric profiling of IL-7-augmented GD2.CART products in a phase 1 clinical trial.
CAR T细胞（CART）疗法在癌症治疗中前景广阔，但产品间的异质性限制了临床疗效，因此系统性地分析产品特征以识别成功预测因素至关重要。
CAR T细胞（CART）疗法在癌症治疗中具有前景，但产品之间的异质性限制了临床有效性，因此系统性的分析对于识别成功的预测因素至关重要。最近，一项1期临床试验研究了组成性激活的IL-7受体（C7R）是否能安全地改善GD2靶向CART（GD2.CART）在高级别CNS肿瘤儿科患者中的功能和持久性。我们使用定制设计的33色全光谱流式细胞术（FSFC）panel结合基于图像的肿瘤杀伤试验，分析了试验参与者的输注产品，以表征CART产品并评估C7R对GD2.CART性能的影响。T细胞组成的患者特异性差异与治疗成功相关，与仅CAR产品相比，C7R共表达增强了GD2.CART的功能表型。无监督聚类识别出与临床反应相关的CD8 + T细胞，其特征为活化、浸润、韧性和细胞毒性。我们基于FSFC的分析方法揭示了CART疗效的决定因素，并支持优化过继性免疫治疗的策略。
CAR T cell (CART) therapy holds promise for cancer treatment, but heterogeneity among products limits clinical effectiveness, making systematic profiling essential to identify predictors of success. Recently, a phase 1 clinical trial investigated whether a constitutively active IL-7 receptor (C7R) could safely improve the function and persistence of GD2-directed CARTs (GD2.CARTs) in pediatric patients with high-grade CNS tumors. We analyzed infusion products from trial participants using a custom-designed 33-color full spectrum flow cytometry (FSFC) panel combined with an image-based tumor killing assay to characterize CART products and evaluate the impact of C7R on GD2.CART performance. Patient-specific variations in T cell composition were linked to therapeutic success, with C7R co-expression enhancing the functional phenotype of GD2.CARTs compared to CAR-only products. Unsupervised clustering identified CD8 + T cells associated with clinical responses, marked by activation, infiltration, resilience, and cytotoxicity. Our FSFC-based profiling approach reveals determinants of CART efficacy and supports strategies to optimize adoptive immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
